| Cholesterol-lowering strategies reduce vascular LRP1 overexpression induced by hypercholesterolaemia. | |
| | |
MedLine Citation:
|
PMID: 21434892 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Eur J Clin Invest 2011 ABSTRACT: Background Low density lipoprotein receptor-related protein (LRP1) plays a key role on vascular functionality and is upregulated by hypercholesterolemia and hypertension. To investigate the effect of cholesterol-lowering interventions on vascular LRP1 over expression and whether simvastatin influences LRP1 expression. Material and methods Male New Zealand rabbits were recruited into various groups, one group was fed a normal chow diet for 28 days (control group, n = 6), other group (n = 24) was fed a hypercholesterolemic diet (HC), six rabbits were euthanized at day 28 to test the capacity of HC diet to induce early atherosclerosis and the rest at day 60 (n = 18) after receiving either HC diet (HC group, n = 6), HC diet with simvastatin (2·5 mg/kg.day) (HC+simv group, n = 6), or a normal chow diet (NC group, n = 6) for the last 32 days. Results High-cholesterol diet raised vascular LRP1 concomitantly with increased lipid, VSMC and macrophage content in the arterial intima. Simvastatin and return to normocholesterolemic diet significantly reduced systemic cholesterol levels and vascular lipid content. Interestingly, these interventions also downregulate LRP1 overexpression in the vascular wall although to a different extent (HC+simv: 75 ± 3·6%vs NC: 50 ± 3·5% versus, P = 0·002). Immunohistochemistry studies showed that LRP1 diminushion was associated to a reduction in the number of intimal VSMC in HC+simv.group. Simvastatin per se did not exert any significant effect on LRP1 expression in rabbit aortic smooth muscle cells (rSMC). Conclusions Our results demonstrate that cholesterol-lowering interventions exerted down regulatory effects on vascular LRP1 over expression induced by hypercholesterolemia and that simvastatin did not influence LRP1 expression beyond its cholesterol-lowering effects. |
| | |
Authors:
|
Vicenta Llorente-Cortes; Laura Casani; Roi Cal; Albert Llenas; Oriol Juan-Babot; Sandra Camino-López; Judith Sendra; Lina Badimon |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-3-24 |
Journal Detail:
|
Title: European journal of clinical investigation Volume: - ISSN: 1365-2362 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-3-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0245331 Medline TA: Eur J Clin Invest Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation. |
Affiliation:
|
Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau-UAB, Barcelona, Spain CIBEROBN-Instituto Salud Carlos III (L.B.), Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Strengthening the reporting of genetic risk prediction studies: the GRIPS statement.
Next Document: Cyclosporine metabolic side effects: association with the WNK4 system.